このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Celularity マネジメント

マネジメント基準チェック /34

現在、CEO に関する十分な情報がありません。

主要情報

Bob Hariri

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	3yrs
CEOの所有権	13.1%
経営陣の平均在職期間	2yrs
取締役会の平均在任期間	3yrs

経営陣の近況

Recent updates

Celularity Inc. (NASDAQ:CELU) Held Back By Insufficient Growth Even After Shares Climb 80%

Feb 14

News Flash: Analysts Just Made A Massive Upgrade To Their Celularity Inc. (NASDAQ:CELU) Forecasts

Dec 14

Celularity: Celgene Spin-Off Developing Allogeneic Therapies

Sep 06

CEO報酬分析

Celularity の収益と比較して、Bob Hariri の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2023	n/a	n/a	-US$181m
Jun 30 2023	n/a	n/a	-US$83m
Mar 31 2023	n/a	n/a	US$13m
Dec 31 2022	US$5m	US$1m	US$14m
Sep 30 2022	n/a	n/a	-US$14m
Jun 30 2022	n/a	n/a	US$31m
Mar 31 2022	n/a	n/a	-US$81m
Dec 31 2021	US$22m	US$1m	-US$100m
Sep 30 2021	n/a	n/a	-US$92m
Jun 30 2021	n/a	n/a	-US$188m
Mar 31 2021	n/a	n/a	-US$260m
Dec 31 2020	US$3m	US$1m	-US$208m

報酬と市場: Bobの総報酬がUS市場の同規模の企業と比較して妥当かどうかを判断するにはデータが不十分です。

報酬と収益: Bobの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Bob Hariri (65 yo)

3yrs

在職期間

US$5,242,529

報酬

Dr. Robert Joseph Hariri, also known as Bob, M.D., Ph.D. is a Co-Founder of Human Longevity, Inc. and serves as President of Human Longevity Cellular Therapeutics. He serves as Medical Advisor at Beyond Im...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Robert Hariri	Founder	3yrs	US$5.24m	13.07% $ 8.7m
David Beers	Chief Financial Officer	3yrs	US$1.71m	0.034% $ 22.4k
John Haines	Senior EVP	1.8yrs	US$2.50m	0.0049% $ 3.2k
Ramji Krishnan	Chief Technology Officer	1.1yrs	データなし	データなし
Carlos Ramirez	SVP of Investor Relations	no data	データなし	データなし
Kyle Fletcher	Executive VP	2yrs	データなし	0.0034% $ 2.2k
Stephen Brigido	President of Degenerative Diseases	3yrs	データなし	0.0025% $ 1.7k
Adrian Kilcoyne	Executive VP	1.8yrs	データなし	0.52% $ 341.2k
Sharmila Koppisetti	Senior Vice President of Clinical Dev. Immunology & Drug Safety	2.5yrs	データなし	データなし
Tim Wilk	Senior Vice President of Technical Operations	1.1yrs	データなし	データなし
David Lemus	Treasurer	no data	データなし	データなし
Timothy Smith	Secretary	no data	データなし	データなし

2.0yrs

平均在職期間

54yo

平均年齢

経験豊富な経営陣: CELUの経営陣は経験豊富であると考えられます ( 2年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Robert Hariri	Founder	3yrs	US$5.24m	13.07% $ 8.7m
Diane Parks	Independent Director	2.1yrs	US$627.68k	0.017% $ 11.0k
Louis Weiner	Member of Scientific Advisory Board	2.5yrs	データなし	データなし
Dean Kehler	Independent Director	6.5yrs	US$373.00k	0.85% $ 561.0k
Peter Diamandis	Independent Director	3yrs	US$353.50k	0.51% $ 336.6k
Marc Mazur	Independent Director	5.2yrs	US$371.00k	0.039% $ 25.9k
Geoffrey Shiu Ling	Director	less than a year	データなし	データなし
Darren Sigal	Co-Chairman of Scientific Advisory Board	no data	データなし	データなし

3.0yrs

平均在職期間

67yo

平均年齢

経験豊富なボード: CELUの取締役会は経験豊富であると考えられます ( 3年の平均在任期間)。

Celularity マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

High number of new and inexperienced directors

Celularity Inc. Announces Resignation of Robin L. Smith, MD, from Board of Directors

Lim Kok Thay Notifies Celularity Inc. of His Intention to Resign as a Member of the Board and All Committees

Celularity Inc. Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors

High number of new and inexperienced directors

Independent Director exercised options to buy US$822k worth of stock.

Recent updates

Celularity Presents Data of the Effect of Its T-Cell Platform on Multiple Hematological and Solid Tumors At the American Society of Clinical Oncology (Asco) Annual Meeting

Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Celularity Inc. announced delayed 10-Q filing

Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

Celularity Inc. announced delayed annual 10-K filing

Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance 3L

Celularity Inc. (NASDAQ:CELU) Held Back By Insufficient Growth Even After Shares Climb 80%

High number of new and inexperienced directors

Celularity Inc. Provides Sales Guidance for the First Quarter and Full Year 2024

Genting Berhad Engages in Discussions with Celularity Inc

Celularity Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Celularity Inc. Announces Resignation of Robin L. Smith, MD, from Board of Directors

Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Celularity Inc. announced delayed 10-Q filing

Lim Kok Thay Notifies Celularity Inc. of His Intention to Resign as a Member of the Board and All Committees

Celularity Inc. Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Celularity Inc. to Present Data from a New Product Technology in Development for Orthopedic Applications at 7th International Conference on Orthopedics

New major risk - Share price stability

Celularity Inc. Announces Results from Exploratory Analysis of Phase 1 Data Evaluating Alterations in Gene and Protein Signatures Associated with Inflammation and Fistula Formation in Patients with Crohn's Disease

Celularity Inc. announced delayed 10-Q filing

Price target decreased by 24% to US$8.63

Consensus revenue estimates decrease by 36%, EPS upgraded

Independent Director exercised options to buy US$822k worth of stock.

Celularity Receives Preliminary Assessment of Product Classification and Jurisdiction for Its Investigational Celularity Tendon Wrap (Ctw)

Celularity Inc. Announces the Suspends of Robert Hariri as Chairman

Price target decreased by 12% to US$9.50

Celularity Inc. Announces in A Preclinical in Vivo Study of Placental Extracellular Matrix

Celularity Inc.'s Placental-Derived Allogeneic Cell Therapy Provides Clinically Meaningful Benefit and Durable Biological Effect in Patients with Moderate to Severe Crohn's Disease in Phase 1, Phase 1b/2a and Phase 1b Studies

Celularity Inc. Appoints Paul Graves as Chief Communications Officer

Consensus forecasts updated

Celularity Inc. Announces Halal Certification of Its Advanced Cellular Therapeutics, Biomaterial Products and Business Model

Founder recently bought US$70k worth of stock

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: US$0.034 (vs US$0.47 in 3Q 2021)

Imugene’s on CARlytics Combination with Celularity’s Placental-derived off-the-shelf Allogeneic CYCART-19 T Cells Preclinical Data Presented at SITC Annual Meeting

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Celularity Promotes Two Executives in Executive Leadership Team

Celularity Appoints Adrian Kilcoyne as Executive Vice President, Chief Medical Officer and Head of Global Affairs, Patient Safety and Patient Affairs

Celularity appoints Adrian Kilcoyne as chief medical officer

Celularity Inc. Publishes New Data in Frontiers in Immunology Demonstrating Placental-Derived Natural Killer Cells (CYNK) Recognized and Eliminated Influenza A Virus (IAV)-Infected Cells in Vitro

Celularity Inc. Announces Resignation of Andrew L. Pecora, M.D., F.A.C.P., as Company’s President Effective as of August 31, 2022

Celularity falls after announcing fund raising deal

Investor sentiment deteriorated over the past week

High number of new and inexperienced directors

Celularity falls 10% on deal for $150M common stock offering

Founder exercised options to buy US$343k worth of stock.

Price target decreased to US$10.60

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Celularity Inc. Announces Treatment of First Patient in Phase 1/2a Clinical Trial for NK Cell Therapy CYNK-101, in Development for the First-Line Treatment of Advanced HER2 Positive Gastric and Gastroesophageal Junction (G/GEJ) Cancers

Celularity begins phase 1/2a trial for cell therapy CYNK-101 to treat cancers

Celularity Inc. Announces the Resignation of Andrew L. Pecora as President, Effective from August 31, 2022

Price target increased to US$11.80

Celularity Inc. Announces Board Changes

Celularity Inc. Appoints Diane Parks to Board of Directors

Celularity Inc. announced that it has received $30.000007 million in funding

Consensus estimates of losses per share improve by 34%

Celularity Inc. announced that it expects to receive $30.000007 million in funding

First quarter 2022 earnings: Revenues exceed analyst expectations

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers

マネジメント基準チェック /34